SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its potential for a short squeeze, fueled by a low float and high short interest, as well as its upcoming presentation at an emerging growth conference. Community members are actively discussing the company's shift towards AI and digital infrastructure, viewing it as undervalued compared to its peers, and anticipating potential catalysts from the conference. The stock's volatile price action and history of explosive moves are also contributing to the heightened interest.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to a mixed earnings report, with concerns arising from increased spending on AI infrastructure and rising debt despite strong cloud growth and a large backlog. Community discussions revolve around whether Oracle can effectively monetize its AI investments, with some questioning the long-term viability of its strategy, while others see a buying opportunity amid the selloff. The broader market is reacting, with some fearing a potential AI bubble burst.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending following news of a national retail distribution agreement with Walmart, causing significant premarket gains. The community is actively discussing potential price targets and whether the stock can sustain its momentum, while also considering potential resistance levels. This development marks AXIL's largest retail placement, expanding access to its hearing protection products.

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Rezolute Inc

Rezolute Inc is trending downwards following the announcement of failed phase 3 trials, leading to a significant drop in stock price and triggering disappointment among investors who had anticipated positive data. The community is discussing the potential reasons for the data miss, possible future actions for the company given its cash reserves, and whether a rebound is possible, while some traders are exploring potential shorting opportunities or bottom-fishing strategies.

iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.

Irobot Corp

iRobot Corp

IRBT is trending as traders discuss a potential short squeeze, citing very high short interest and recent price movement. Community members are pointing to the difficulty in borrowing shares and high borrowing fees as further indicators of a possible squeeze. Some are expressing caution, noting the company's fundamentals and potential for a bull trap.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a potential buyout and the company's recent progress in its DM1 clinical study. Community members are debating the stock's valuation, upcoming milestones, and the potential impact of competitor data, while also analyzing recent analyst ratings and institutional ownership.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending downwards amidst analyst downgrades, most recently from BofA and JP Morgan, with concerns stemming from slowing growth in branded checkout and a perceived lack of management confidence. The community is debating the impact of buybacks, the CEO's performance, and whether the stock is undervalued or a value trap. Some traders express frustration, while others see an opportunity for long-term gains if PayPal can turn things around.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday price surge, fueled by its low float and significant volume, leading to discussions about potential short squeezes and comparisons to other recent high-flying stocks. The community is actively debating whether the run has ended or if there is potential for further gains, with some cautioning about bag holding and others anticipating after-hours momentum. Overall, traders are focused on the stock's volatile price action and potential for quick profits.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as it approaches new lows, sparking discussions about its future and potential S&P 500 exclusion. The community is debating factors like competition from Amazon, tax-loss harvesting, and the CEO's performance amid the stock's significant year-to-date decline. Some investors see a buying opportunity, while others express concerns about the company's ability to compete and innovate.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as traders debate whether its S&P 500 inclusion justifies its high valuation, with some calling it a "scam" and others predicting further gains. Community discussions revolve around potential short squeezes, the influence of interest rate cuts, and concerns about the company's fundamentals versus market hype. Despite the debate, the stock's strong upward momentum has captured significant attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's What Happened...

Geode Capital Management LLC Has $6.66 Million Holdings in Regencell Bioscience Holdings Limited $RGC

Geode Capital Management LLC increased its position in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC - Free Report) by 5,637.5% during the second quarter, according to the company in...

Regencell Bioscience (NASDAQ:RGC) Stock Price Up 17.9% - Time to Buy?

Regencell Bioscience (NASDAQ:RGC) Trading 17.9% Higher - Here's Why...

Regencell Bioscience (NASDAQ:RGC) Trading 11.1% Higher - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Trading 11.1% Higher - Still a Buy...

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 4.2% - What's Next?

Regencell Bioscience (NASDAQ:RGC) Shares Down 4.2% - Here's Why...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Should You Sell?

Regencell Bioscience (NASDAQ:RGC) Trading Up 10.5% - Time to Buy?

Regencell Bioscience (NASDAQ:RGC) Trading 10.5% Higher - Time to Buy...

<a href="https://stocktwits.com/symbol/RGC">Regencell Bioscience Holdings Ltd</a>. (RGC), a Hong Kong-based nano-cap biotech firm, has emerged as one of the most explosive stocks of 2025, skyrocketing 14,486% year-to-date.The staggering rally has captivated retail traders and propelled the stock into the top trending ranks of healthcare chatter on Stocktwits.Over the past three months, message volume surrounding RGC has surged by 17,600% on Stocktwits, while its follower count has jumped 156%, reflecting some of the most intense engagement seen among small-cap health care stocks.Sentiment has mostly remained bullish over the same period, though cracks of doubt have&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">emerged</a> as traders digest the stock’s rise despite no formal news or clear catalysts.<figure class="image"><img style="aspect-ratio:1322/1354;" src="https://news.stocktwits-cdn.com/RGC_YTD_chart_with_sentiment_meter_and_message_volume_as_of_May_29_png_6a489def8e.webp" alt="RGC YTD chart with sentiment meter and message volume as of May 29.png" width="1322" height="1354"><figcaption>RGC YTD chart with sentiment meter and message volume as of May 29. | source: Stocktwits</figcaption></figure>Many retail investors remain wary, with some warning of a looming correction."$RGC one of these days this dumps 99% in [a] single trading session," said one user.<stembedurl>https://stocktwits.com/ItSaulGoodMaan/message/616270456</stembedurl>"$RGC this went up 20,000 % in 3 months, if they didn’t just cure cancer, then this is a scam," said another.<stembedurl>https://stocktwits.com/Lard_ass_piggy/message/616269720</stembedurl>Hong Kong-based Regencell focuses on traditional Chinese medicine (TCM), developing formulas aimed at treating ADHD and autism spectrum disorder (ASD).Despite its mission, the company has yet to commercialize any treatments, apply for regulatory approvals, or secure patents.&nbsp;In its most recent annual filing in October, the firm disclosed net losses of $4.36 million for fiscal 2024 and noted it may “never be profitable.”Insider activity appears to be fueling much of the move. According to media reports, insiders control 81% of the float, limiting public liquidity and potentially amplifying volatility.As of June 30, 2024, Regencell reported $8 million in cash and short-term investments, which it believed was enough to cover expenses for at least the following 12 months. However, it said it will likely need “substantial additional financing” to continue operations.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Biotech Stock's Mind-Blowing 14,400% YTD Rally Draws Frenzied Retail Interest

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.

Equity

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.


Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RGC News

RGCRegencell Bioscience Holdings Ltd